Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint - TheStreet.com

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint  TheStreet.com

Galapagos NV (GLPG) rose sharply Friday after the biotechnology company announced positive results for both doses of its rheumatoid arthritis drug, filgotinib, ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases